COST EFFECTIVENESS OF CYCLOPHOSPHAMIDE IN THE ADJUVANT TREATMENT OF BREAST CANCER IN EUROPE: A MULTI-COUNTRY STUDY

被引：0
|
作者：
Walter, E. [1 ]
Mercsanits, D. [1 ]
机构：
[1] Inst Pharmaecon Res, Vienna, Austria
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.2114
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A422 / A422
页数：1
相关论文
共 50 条
  • [1] COST EFFECTIVENESS OF ADJUVANT CYCLOPHOSPHAMIDE IN THE TREATMENT OF BREAST CANCER IN SPAIN
    Walter, E.
    Brennig, C.
    Schoellbauer, V
    VALUE IN HEALTH, 2011, 14 (07) : A455 - A455
  • [2] COST EFFECTIVENESS OF ADJUVANT CYCLOPHOSPHAMIDE CONTAINING REGIMES TO AT IN THE TREATMENT OF BREAST CANCER IN GERMANY
    Walter, E.
    ANNALS OF ONCOLOGY, 2012, 23 : 121 - 121
  • [3] COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE VERSUS DOXORUBICIN PLUS CYCLOPHOSPHAMIDE IN THE ADJUVANT TREATMENT OF OPERABLE BREAST CANCER
    Jones, S.
    Chen, L.
    Tangirala, M.
    Asmar, L.
    Airia, P.
    Thompson, M. F.
    VALUE IN HEALTH, 2009, 12 (03) : A45 - A45
  • [4] Cost analysis of neonatal and pediatric parenteral nutrition in Europe: a multi-country study
    Walter, E.
    Liu, F. X.
    Maton, P.
    Storme, T.
    Perrinet, M.
    von Delft, O.
    Puntis, J.
    Hartigan, D.
    Dragosits, A.
    Sondhi, S.
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2012, 66 (05) : 639 - 644
  • [5] Cost analysis of neonatal and pediatric parenteral nutrition in Europe: a multi-country study
    E Walter
    F X Liu
    P Maton
    T Storme
    M Perrinet
    O von Delft
    J Puntis
    D Hartigan
    A Dragosits
    S Sondhi
    European Journal of Clinical Nutrition, 2012, 66 : 639 - 644
  • [6] Three versus six months of adjuvant chemotherapy for colorectal cancer: A multi-country cost-effectiveness and budget impact analysis.
    Hanna, Catherine
    Robles-Zurita, Jose Antonio
    Jones, Robert J.
    Boyd, Kathleen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] LONG TERM COST-EFFECTIVENESS OF DOCETAXEL PLUS CYCLOPHOSPHAMIDE COMPARED TO DOXORUBICIN PLUS CYCLOPHOSPHAMIDE AS ADJUVANT TREATMENT FOR WOMEN WITH OPERABLE BREAST CANCER
    Jackson, D.
    Lee, J. M.
    Adams, J.
    Gordois, A.
    VALUE IN HEALTH, 2009, 12 (07) : A274 - A274
  • [8] Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis
    Hanna, Catherine R.
    Robles-Zurita, Jose A.
    Briggs, Andrew
    Harkin, Andrea
    Kelly, Caroline
    McQueen, John
    Allan, Karen
    Pearson, Sarah
    Hollander, Henrik
    Glimelius, Bengt
    Salazar, Ramon
    Segelov, Eva
    Saunders, Mark
    Iveson, Tim
    Jones, Robert J.
    Boyd, Kathleen A.
    CLINICAL COLORECTAL CANCER, 2021, 20 (03) : 236 - 244
  • [9] TAS-102 with or without bevacizumab treatment for patients with metastatic colorectal cancer: a multi-country cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Zhu, Hong
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
  • [10] Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer - A lifetime model
    Millar, J. Alasdair
    Millward, Michael J.
    PHARMACOECONOMICS, 2007, 25 (05) : 429 - 442
12345